Nothing Special   »   [go: up one dir, main page]

BR0208012A - Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma - Google Patents

Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma

Info

Publication number
BR0208012A
BR0208012A BR0208012-5A BR0208012A BR0208012A BR 0208012 A BR0208012 A BR 0208012A BR 0208012 A BR0208012 A BR 0208012A BR 0208012 A BR0208012 A BR 0208012A
Authority
BR
Brazil
Prior art keywords
inhaler
packaged
drugs
pharmaceutical composition
hfa
Prior art date
Application number
BR0208012-5A
Other languages
English (en)
Inventor
Robert Leonard Kunka
Tushar Pannalal
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0208012A publication Critical patent/BR0208012A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USOS DE PELO MENOS DUAS DROGAS E UM PROPELENTE HFA E DE PELO MENOS UMA COMPOSIçãO FARMACêUTICA, E, INALADOR ACONDICIONADO PARA TRATAR ASMA". é descrito um método para tratar distúrbios respiratórios pela administração, por inalação, de uma quantidade eficaz de um agonista de receptor-<225>~ 2~, uma quantidade de um corticosteróide e HFA 134a a um paciente em necessidade dela. Preferivelmente, o agonista do receptor-<225>~ 2~ é salmeterol ou um seu sal fisiologicamente aceitável e o corticosteróide é propionato de fluticasona ou um seu solvato. A combinação de salmeterol, propionato de fluticasona e HFA 134a pode diminuir o risco de arritmias cardíacas, morte súbita ou hipercorticoidismo, que são às vezes associados com a administração simultânea de um agonista de receptor-<225>~ 2~ e um corticosteróide antiinflamatório.
BR0208012-5A 2001-03-20 2002-03-18 Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma BR0208012A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27722901P 2001-03-20 2001-03-20
PCT/US2002/008067 WO2002080859A2 (en) 2001-03-20 2002-03-18 Inhalation drug combinations

Publications (1)

Publication Number Publication Date
BR0208012A true BR0208012A (pt) 2004-03-02

Family

ID=23059937

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208012-5A BR0208012A (pt) 2001-03-20 2002-03-18 Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma

Country Status (5)

Country Link
US (3) US20040197271A1 (pt)
AR (1) AR033179A1 (pt)
BR (1) BR0208012A (pt)
IL (1) IL157580A0 (pt)
WO (1) WO2002080859A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US7370797B1 (en) * 1996-05-31 2008-05-13 Scott Lindsay Sullivan Pill printing and identification
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP4521183B2 (ja) * 2001-06-21 2010-08-11 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド 組織および臓器移植の転帰を改善しかつアポトーシスを抑制する一酸化炭素
CN100393323C (zh) * 2002-02-13 2008-06-11 贝思·伊斯雷尔·迪科尼斯医药中心 治疗血管疾病的方法
ES2546280T3 (es) * 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
EP1499186A4 (en) 2002-04-15 2009-10-28 Beth Israel Hospital USE OF HEME-OXYGENASE-1 AND HEME DEGRADATION PRODUCTS
CA2481786A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
JP4549847B2 (ja) 2002-05-17 2010-09-22 イエール ユニバーシティ 肝炎の治療方法
EP1509237A4 (en) * 2002-06-05 2006-07-12 Univ Yale PROCESS FOR TREATING ANGIOGENESIS, TUMOR GROWTH AND METASTASES
EA200500062A1 (ru) * 2002-06-21 2005-06-30 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Фармацевтическое применение оксида азота, гемоксигеназы-1 и продуктов деградации гема
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
US20100163033A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163029A1 (en) 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for administering an inhalable compound
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
LT3111927T (lt) * 2009-05-29 2020-03-25 Pearl Therapeutics, Inc. Kompozicijos veikliųjų agentų respiraciniam peteikimui ir susiję būdai ir sistemos
WO2012054718A2 (en) * 2010-10-22 2012-04-26 The General Hospital Corporation Treating long qt syndrome
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
CA3012333A1 (en) 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
US10441537B2 (en) 2017-05-10 2019-10-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3768378A4 (en) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. NEW METHOD TO SLOW THE VENTRICULAR RATE
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH24267A (en) * 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
US4423829A (en) * 1980-08-28 1984-01-03 Container Industries Inc. Apparatus for containing and dispensing fluids under pressure and method of manufacturing same
US4387833A (en) * 1980-12-16 1983-06-14 Container Industries, Inc. Apparatus for containing and dispensing fluids under pressure and method of producing same
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2639567B1 (fr) * 1988-11-25 1991-01-25 France Etat Machine a microfaisceau laser d'intervention sur des objets a couche mince, en particulier pour la gravure ou le depot de matiere par voie chimique en presence d'un gaz reactif
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration

Also Published As

Publication number Publication date
WO2002080859A3 (en) 2002-11-28
US20070122351A1 (en) 2007-05-31
IL157580A0 (en) 2004-03-28
AR033179A1 (es) 2003-12-10
US20040197271A1 (en) 2004-10-07
US20070122352A1 (en) 2007-05-31
WO2002080859A2 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
Crompton A brief history of inhaled asthma therapy over the last fifty years
JP5399898B2 (ja) 神経因性疼痛の治療用カンナビノイド
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
ES2342463T3 (es) Formulacion superfina de formoterol.
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
AR101593A2 (es) Formulación superfina de formoterol
US20050180926A1 (en) Inhalable aerosol medicament for the treatment or prevention of pain
CO5031245A1 (es) Inhaladores de dosis regulada a presion y formulaciones farmaceuticas de aerosol
ATE216575T1 (de) Treibgasmischung für eine aerosolzubereitung
KR920017643A (ko) 약제학적 에어로졸 제제
RU94030722A (ru) Аэрозольная фармацевтическая композиция, лекарственное средство с модифицированной поверхностью, баллон для доставки фармацевтической композиции, ингалятор, способ лечения респираторных заболеваний
BR0008039A (pt) Combinações de formoterol e um sal de tiotrópio
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
BRPI0312128B8 (pt) formulação farmacêutica compreendendo azelastina e éster de fluticasona
KR20010052721A (ko) 급성 천식 질환의 예방 또는 치료를 위한 포르모테롤 및부데소니드를 포함하는 조성물의 용도
BRPI0719203A2 (pt) Uso de fármacos indutores de hipotermia
WO2009124552A2 (en) Use of a combination of hypothermia inducing drugs
WO2009124553A2 (en) Use of hypothermia inducing drugs
AR040450A1 (es) Formulacion superfina de salmeterol
SK2302003A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
WO2009071096A2 (en) Combination of medical and physical cooling treatment of ischemic effects
KR20080059229A (ko) 정상적 호흡 리듬의 회복을 위한 ｓ-니트로소티올계 조합제약 생성물
JP2005508963A (ja) 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
CO5690570A2 (es) Nueva combinacion sinergistica que comprende roflumilast y formoterol

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]